The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC


Viola Poeschel, MD, discusses findings from the phase III FLYER trial and how they will impact the treatment landscape for younger patients with favorable-prognosis DLBCL.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.